|
Actelion's novel CRTH2 antagonist meets primary endpoint in Phase II study in …
Reuters (press release) This study complements the positive proof-of-mechanism study in asthma reported in 2009. Together, these studies provide substantial information that will guide us in the further development of this compound and our follow-up molecules in allergic … |
View full post on asthma – Google News